Atrial natriuretic peptide antagonists: biological evaluation and structural correlations

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Endocrinology

Background:

• Atrial natriuretic peptide (ANP) plays a crucial role in regulating blood pressure and fluid balance.
• The mechanism of ANP action involves stimulating cyclic guanosine monophosphate (cGMP) production.
• Understanding ANP signal transduction is vital for developing cardiovascular therapeutics.

Purpose of the Study:

• To screen for novel antagonists of ANP-induced cGMP stimulation.
• To investigate the role of specific amino acid residues in ANP/cGMP signal transduction.
• To characterize the pharmacological profile of a potent ANP antagonist, A74186.

Main Methods:

• Screening of ANP analogues for inhibition of ANP-stimulated cGMP.
• Structure-activity relationship analysis of identified antagonists.
• In vitro assays using rat vascular smooth muscle cells to determine pA2 and dose-response curves.
• In vivo studies to assess the effects of A74186 on natriuresis, diuresis, and blood pressure.

Main Results:

• Several ANP analogues inhibited ANP-induced cGMP, with substitutions at Asp-13 or Phe-26 being common.
• Compound A74186 potently inhibited ANP-stimulated guanylate cyclase activation (pA2 = 7.12) and ANP/cGMP dose-response curves.
• A74186 abolished ANP-induced natriuresis and diuresis in vivo but acted as an agonist for ANP's hypotensive and vasorelaxant effects.

Conclusions:

• Specific amino acid residues (Asp-13, Phe-26) are critical for ANP/cGMP signal transduction.
• cGMP mediates the renal effects of ANP but not its vascular or hemodynamic actions.
• A74186 is a valuable tool for dissecting the distinct signaling pathways of ANP.